CXCR4-targeted PET/CT with [¹⁸F]AlF-NOTA-QHY-04 in primary central nervous system lymphoma: a prospective comparison with MRI and [¹⁸F]FDG PET/CT
A new brain-imaging agent detects lymphoma as well as MRI but beats standard PET scans, offering doctors another tool to catch disease recurrence.
A prospective study of 29 PCNSL patients demonstrates that the novel CXCR4-targeted PET agent [¹⁸F]AlF-NOTA-QHY-04 achieves diagnostic accuracy comparable to MRI while dramatically outperforming FDG-PET, offering a potentially valuable non-invasive imaging option for PCNSL diagnosis and restaging. The very high tumor-to-background ratio suggests superior lesion detection, particularly relevant for recurrence assessment where MRI can be confounded by treatment changes.
What the study was
- Study design
- Prospective comparative diagnostic study
- Population
- Patients with suspected primary CNS lymphoma (initial diagnosis and suspected recurrence)
- Sample size
- 29
- Category
- Diagnostics
- Maturity
- Validated
- Journal
- European Journal of Nuclear Medicine and Molecular Imaging
Why it surfaced
Prospective validation of novel CXCR4-targeted PET agent with AUC=0.979 in PCNSL, significantly outperforming FDG-PET; directly relevant to lymphoma diagnosis and restaging workflow.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.